Posted by Michael Wonder on 21 Apr 2018
FDA commissioner to drug middlemen: you're part of the problem
19 April 2018 - The FDA has approved nine biosimilars, generic versions of biologic medicines, but only three are available in the U.S.
Drug makers may not be the only ones keeping less-expensive drugs off the market.
Manufacturers are using several schemes to "hamstring biosimilar competition," FDA Commissioner Scott Gottlieb said at the Pharmaceutical Care Management Association's PBM Policy Forum, according to a copy of his prepared remarks.
